Daily Ards Research Analysis
Analyzed 14 papers and selected 3 impactful papers.
Summary
A mechanistic study identifies NINJ1 as a pore-forming driver of neutrophil extracellular trap release in ALI/ARDS, revealing druggable oligomerization interfaces. A multicenter phase 1 trial suggests intravenous human umbilical cord MSCs are safe in mild-to-moderate ARDS with a mid-dose efficacy signal. Preclinical work shows a dual-component herbal formulation (DMD) modulates HMGB1 signaling at distinct nodes to attenuate lung inflammation.
Research Themes
- Neutrophil extracellular traps and pore-forming proteins in ALI/ARDS
- Cell-based therapies for ARDS (human umbilical cord MSCs)
- HMGB1-targeted multi-node modulation of pulmonary inflammation
Selected Articles
1. NINJ1 plays a vital role in the release of neutrophil extracellular traps during acute lung injury.
Using human ARDS neutrophils and ALI mouse models, the authors show that NINJ1 oligomerization is required for NET release and drives lung injury. Targeting key residues (K45, N60) prevents NET extrusion, improves pulmonary function, and reduces lethality, nominating NINJ1 as a therapeutic target.
Impact: This is a first demonstration that a pore-forming protein (NINJ1) governs NET release in ALI/ARDS, defining actionable interfaces for drug development.
Clinical Implications: NINJ1 inhibitors that disrupt oligomerization could attenuate NET-driven lung injury in ARDS; NET and NINJ1 markers may aid patient stratification for future trials.
Key Findings
- NINJ1 is highly expressed in pro-inflammatory neutrophil subpopulations during ALI based on single-cell transcriptomics.
- NINJ1 oligomerization is essential for NET release in neutrophils from ARDS patients and ALI mice.
- Neutrophil-specific Ninj1 deletion abolishes NET release, improves lung function, and reduces ALI-related mortality.
- K45 and N60 residues are critical for NINJ1 oligomerization and subsequent NET extrusion.
Methodological Strengths
- Integrated human (ARDS neutrophils) and mouse (ALI) models with genetic ablation.
- Combines single-cell transcriptomics with functional assays to define mechanism.
Limitations
- Preclinical study without therapeutic NINJ1 inhibitors tested in vivo.
- Patient sample sizes and clinical covariates are not detailed in the abstract.
Future Directions: Develop and test small molecules or antibodies that block NINJ1 oligomerization; evaluate biomarker-guided strategies to target NETs in ARDS.
Excessive neutrophil extracellular traps (NETs) formation is a significant contributor to acute lung injury (ALI), making its inhibition a novel therapeutic avenue to improve outcomes. In this study, we revealed that a novel pore-forming protein ninjurin-1 (NINJ1) was highly expressed in pro-inflammatory neutrophil subpopulations during ALI, using public single-cell RNA sequencing and hotspot analysis. Furthermore, we demonstrated that the NINJ1 oligomerization was essential for the NET release in neutrophils from both acute respiratory distress syndrome (ARDS) patients and ALI mice. Genetic ablation of Ninj1 in neutrophils abolished NET release, thereby attenuating pulmonary dysfunction and reducing ALI-related lethality. Mechanistically, we found that K45 and N60 are critical for NINJ1 oligomerization and subsequent NET release. In summary, our findings reveal a novel pore-forming protein-mediated mechanism for NET release and highlight NINJ1 as a potential therapeutic target for the treatment of ALI/ARDS.Schematic illustration. The novel pore-forming protein NINJ1 mediates the extrusion of NETs, thereby exacerbating pulmonary injury in ARDS/ALI. K45 and N60 are essential for NINJ1 oligomerization and subsequent NET release.
2. The safety and efficacy of human umbilical cord mesenchymal stem cell for acute respiratory distress syndrome: an open-label and multicenter phase 1 clinical trial.
In a multicenter, open-label 3+3 dose-escalation trial (n=12), a single IV infusion of allogeneic hUC-MSCs in mild-to-moderate ARDS was safe and well tolerated over 28 days. Preliminary signals favored the middle dose, and exploratory immune readouts were collected to inform future trial design.
Impact: Provides prospective human safety data and dose-ranging signals for cell therapy in ARDS, directly enabling the next phase of randomized trials.
Clinical Implications: While not practice-changing, the data support proceeding to adequately powered RCTs and suggest mid-dose regimens may balance safety and efficacy.
Key Findings
- Open-label multicenter phase 1 trial enrolled 12 ARDS patients in a 3+3 dose-escalation design across three dose tiers.
- Single IV infusion of allogeneic hUC-MSCs was safe and well tolerated over 28 days.
- Preliminary efficacy signal was most evident in the middle dose group.
- Exploratory immune profiling (immunoglobulins, cytokines, lymphocyte subsets) was incorporated.
Methodological Strengths
- Prospective multicenter 3+3 dose-escalation design appropriate for phase 1 safety.
- Standardized 28-day follow-up with exploratory immune endpoints.
Limitations
- Small sample size (n=12) without a control arm limits efficacy inference.
- Open-label design and baseline severity imbalance in the high-dose group.
Future Directions: Proceed to multicenter randomized controlled trials powered for clinical endpoints; refine dose selection based on safety and preliminary efficacy signals.
TRIAL DESIGN: Acute Respiratory Distress Syndrome (ARDS) remains a life-threatening critical illness with high mortality and limited specific therapies. This open-label, multicenter Phase I clinical trial aimed to evaluate the safety, tolerability, and preliminary efficacy of allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs, BC-U001) in patients with mild-to-moderate ARDS. A total of 12 eligible patients were enrolled into three dose groups following a "3 + 3" dose-escalation design from 2019 to 2024. METHODS: All patients received standard ARDS care plus a single intravenous infusion of BC-U001, with 28-day follow-up to assess safety and efficacy as well as exploratory immunological indicators (immunoglobulins, inflammatory cytokines, lymphocyte subsets). RESULTS: Baseline characteristics were balanced across groups except for more severe baseline lung injury in high dose patients ( CONCLUSIONS: These findings demonstrate that hUC-MSCs are safe and well-tolerated in mild-to-moderate ARDS patients, with the middle dose showing promising therapeutic effects. This trial provides critical data to support the design of future large-scale, randomized controlled trials to confirm the efficacy of hUC-MSCs for ARDS.
3. Dahuang-mudanpi decoction mitigates ALI/ARDS pulmonary inflammation via multi-target regulation of HMGB1.
In LPS-induced ALI mice, DMD reduced lung injury (W/D ratio, histology) and inflammatory cytokines. Paeonol likely targets the HMGB1 NLS1 region to block nuclear translocation and release, while emodin interacts near the receptor-binding site to blunt extracellular HMGB1 signaling, indicating complementary multi-node HMGB1 modulation.
Impact: Offers mechanistic clarity on how two defined small molecules modulate distinct HMGB1 nodes to suppress lung inflammation, suggesting a rational combination strategy.
Clinical Implications: While preclinical, the dual targeting of HMGB1 nuclear translocation and extracellular signaling could inspire combination therapeutics for ALI/ARDS pending pharmacokinetic and safety studies.
Key Findings
- DMD significantly reduced LPS-induced lung injury and inflammatory cytokines (IL-1β, TNF-α, IL-6, HMGB1).
- Paeonol is predicted to bind HMGB1 NLS1 (Vina −4.7 kcal/mol), inhibiting nuclear translocation and extracellular release.
- Emodin is predicted to bind near the HMGB1 receptor-binding region (Vina −6.3 kcal/mol), suppressing extracellular HMGB1 activity.
- HPLC quantified active compounds; outcomes included lung W/D ratio and histopathologic injury scores.
Methodological Strengths
- In vivo ALI model with quantitative physiologic and histologic endpoints.
- Chemical characterization of DMD by HPLC and complementary mechanistic assays including docking.
Limitations
- Molecular docking provides supportive but not definitive binding evidence; no direct biophysical validation.
- Small per-group sample sizes and lack of pharmacokinetic/toxicity profiling limit translation.
Future Directions: Validate direct HMGB1 binding (e.g., SPR/ITC), optimize dosing and pharmacokinetics, and test combination or analogs in multiple ALI/ARDS models.
BACKGROUND: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe inflammatory conditions with high mortality and limited treatment options. Targeting pulmonary inflammation is a critical strategy for improving clinical outcomes. This study was performed to investigate the therapeutic effects and underlying mechanisms of Dahuang-Mudanpi Decoction (DMD), specifically focusing on its active ingredients, paeonol (PAE) and emodin (EMO), and their regulatory role in high mobility group box 1 (HMGB1)-mediated inflammation in ALI/ARDS. METHODS: The therapeutic efficacy of DMD was evaluated using a lipopolysaccharide (LPS)-induced ALI mouse model (n = 8 per group for the DMD dose-screening experiment and n = 6 per group for the component-comparison experiment). High-performance liquid chromatography (HPLC) was employed to quantify the active compounds within DMD. The protective effects were comprehensively assessed by analyzing body weight changes, lung wet/dry (W/D) ratios, and histopathological lung injury scores. Additionally, systemic and localized inflammatory responses were evaluated by measuring hematological parameters and the levels of key inflammatory cytokines, including interleukin-1 beta (IL-1β), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and HMGB1. Data were analyzed using one-way analysis of variance (ANOVA) or nonparametric tests, as appropriate. RESULTS: DMD administration significantly mitigated LPS-induced pulmonary inflammation and attenuated lung injury in the mouse model. Mechanistic evaluations revealed distinct, complementary roles for DMD's active components, with molecular docking providing supportive structural evidence rather than definitive proof of direct molecular binding. Specifically, PAE was predicted to interact with the first nuclear localization signal (NLS1) region of HMGB1 (Vina score: -4.7 kcal/mol), which corresponded to its observed ability to effectively inhibit the nuclear translocation of HMGB1 and reduce its extracellular release. Conversely, EMO was predicted to bind near the receptor-binding region of HMGB1 (Vina score: -6.3 kcal/mol), suppressing the pro-inflammatory function of extracellular HMGB1. CONCLUSION: These findings demonstrate the multi-target regulatory effects of DMD in mitigating ALI-associated inflammation, highlighting PAE and EMO as promising therapeutic agents for ALI/ARDS. The mechanistic insights provide novel perspectives on HMGB1-targeted treatments, suggesting that further optimization of this compound combination could yield advanced therapeutic strategies for severe pulmonary inflammation.